(Reuters) – Pfizer Inc and OPKO Health Inc said on Friday the U.S. health regulator declined to approve their application for the experimental growth hormone treatment somatrogon.
(Reporting by Leroy Leo)
U.S. FDA declines to approve Pfizer and OPKO’s growth hormone treatment
Jan 21, 2022 | 3:47 PM
